A new HIV drug has the public and healthcare officials talking this week, as Reuters reported this Friday, Feb. 17, that the U.S. has given priority review status for a still in-the-works GlaxoSmithKline (GSK) drug for HIV/AIDS. Medical analysts have already noted this new treatment could be a potential multibillion seller if approved.
When new medicines have a high possibility of offering patients improved treatment, the U.S. Food and Drug Administration provides drugs with priority status for more immediate experimentation and use.
Now a new HIV drug known now as dolutegraver is under consideration to be approved later this August 2013 to help patients affected with HIV/AIDS. The GSK drug would be a once-daily medicine that aims to help block the AIDS virus from even entering other cells.
So far, the new HIV drug is showing very encouraging results in clinical settings, says the report. Medical analysts add that dolutegravir may soon be seen as a very strong competitor to current HIV treatments from the current leader in the health market, Gilead Sciences.